We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SAB-185

News List

SAB Biotherapeutics’ SAB-185 shows activity against Omicron variant in study Pharmaceutical-Technology
December 20, 2021
SAB Biotherapeutics has reported that its antibody SAB-185 for Covid-19 retained neutralisation activity against the Omicron variant of SARS-CoV-2 in an in vitro pseudovirus model.
NIH trial to evaluate antibody therapy for Covid-19 treatment pharmaceutical-technology
April 23, 2021
The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully human polyclonal antibody therapeutic called SAB-185 for treating Covid-19 in non-hospitalised individuals with mild or moderate ...
SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185 pharmaceutical-business-review
August 14, 2020
SAB Biotherapeutics, a US-based clinical-stage company, has dosed the first participant of a phase 1 study of SAB-185, its therapeutic candidate for Covid-19, in healthy volunteers.